Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), primarily known for managing hypertension and heart failure, have shown promising potential in addressing OA due to their ability to modulate the renin-angiotensin-aldosterone system [RAAS; (157–160)]. Here, ACE is linked to heart failure.